Posted inNeurology news Rheumatology
Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial
The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 weeks.
